We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

Robin Tuohy's testimony at CEPAC on Treatment Options for Relapsed and Refractory Myeloma

On May 26, 2016, the International Myeloma Foundation’s Senior Director of Support Groups and spouse of Michael Tuohy, a sixteen-year myeloma survivor, testified at the Comparative Effectiveness Public Advisory Council’s Public Meeting (CEPAC) on Treatment Options for Relapsed and Refractory Myeloma. In her compelling testimony, Robin shared how her husband Michael’s survival as a myeloma patient may not have been possible without access to a clinical trial, an oral therapy regimen, he has been on for the past eleven years. She pointed out, “Today we are able to treat myeloma in sequence and in combination that reflects our individual disease markers, chromosomal abnormalities, and yes, even side-effect management and quality of life choices. I’ll say that again:  choices!” She urged the Institute of Clinical and Economic Review (ICER), that while their recent report was “well-intended,” when it comes to patient care, “This is a very slippery slope that should not give anyone leverage to limit or deny access to treatment.” 


The IMWG Conference Series "Making Sense of Treatment"
7th IMWG Summit | June 9, 2016

Drs. Brian GM Durie, Joseph Mikhael,Paul Richardson, and Maria Victoria Mateos discusses the latest news and trends in the treatment of Multiple Myeloma.


Living Well with Myeloma:
What you Need to Know to Overcome Side Effects from Novel Therapies

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Multiple Myeloma Program
Cleveland, OH  

Kevin Brigle, PhD, NP
VCUHS Massey Cancer Center
Richmond, VA  


International Myeloma Foundation Brings Together 100 of the World’s Top Myeloma Experts June 7-9, 2016 in Copenhagen for 7th Annual Summit

Addressing Rising Cost of Myeloma Treatments to Be a Key Focus


Pierre S. Sayad Joins IMF as Senior Vice President, Global Medical Affairs and Strategic Partnerships

International Myeloma Foundation Honors Dr. S. Vincent Rajkumar With the 2016 Robert A. Kyle Lifetime Achievement Award

Given in Recognition of Significant Contributions to Myeloma Research and Patient Care


ASCO 2016: More Excitement About Daratumumab (Darzalex®) and Tremendous Interest in Value and Costs
As usual, far fewer myeloma-related abstracts will be presented at next month’s annual meeting of the American Society of Clinical Oncology (ASCO) than are presented at the annual meeting of the American Society of Hematology (ASH) each December. But, writes IMF Chairman Dr. Brian Durie in his blog this week, the results of the Phase III CASTOR study have created some excitement, and the subjects of “cost” and “value” in cancer treatment are definitely in the air! To read Dr. Durie’s blog, click HERE.

Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin-derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 1, 2016 is the deadline for applications. For more information and grant applications, click HERE.

International Myeloma Foundation (IMF) Says Controversial Drug Cost Report Could Limit Patient Access to Optimal Treatment

 IMF Raises Red Flags in Advance of May 26 Hearing, Offers Alternate Approach


Janssen’s Single-Agent DARZALEX® (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)
The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for Darzalex (daratumumab) for the treatment of adults with relapsed and refractory multiple myeloma. Darzalex is to be used in patients whose previous treatment included a proteasome inhibitor and an immunomodulatory agent (other types of cancer medicines) and whose disease worsened after treatment.

previous     next      view all